Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of metronidazole followed by KAL-001 for bacterial vaginosis
ChiCTR2400084774Phase 2Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- May 2024
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of metronidazole and KAL_001 in bacterial vaginosis (BV) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Clinical cure rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
metronidazoleKAL_001
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on ChiCTR2400084774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084774.